Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain

Journal of Biological Chemistry

Volumn 290, Issue 17, 2015, Pages 11061-11074

  Tokarski, John S ^a   Zupa Fernandez, Adriana ^a   Tredup, Jeffrey A ^a   Pike, Kristen ^a   Chang, ChiehYing ^a   Xie, Dianlin ^a   Cheng, Lihong ^a   Pedicord, Donna ^a   Muckelbauer, Jodi ^a   Johnson, Stephen R ^a   Wu, Sophie ^a   Edavettal, Suzanne C ^a   Hong, Yang ^a   Witmer, Mark R ^a   Elkin, Lisa L ^a   Blat, Yuval ^a   Pitts, William J ^a   Weinstein, David S ^a   Burke, James R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BACTERIOPHAGES; CHEMICAL ACTIVATION; CRYSTAL STRUCTURE; ENZYMES; LYMPHOCYTES; MOBILE SECURITY; T-CELLS;

ATP-BINDING SITE; CATALYTIC DOMAINS; CELLULAR ACTIVITIES; COMPOUND LIBRARIES; INHIBITORY PROFILES; SELECTIVE AGENTS; TRANSCRIPTIONAL RESPONSE; TYPE I INTERFERONS;

SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; INTERLEUKIN 2; INTERLEUKIN 23; JANUS KINASE 2; THROMBOPOIETIN; INTERLEUKIN 2 RECEPTOR; JAK1 PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 3; MPL PROTEIN, HUMAN; PROTEIN KINASE TYK2; THROMBOPOIETIN RECEPTOR; TYK2 PROTEIN, HUMAN;

ARTICLE; AUTOIMMUNITY; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEMBRANE STABILIZATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME STABILITY; ENZYMOLOGY; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; ENZYME STABILITY; HUMANS; JANUS KINASE 1; JANUS KINASE 3; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-2; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TYK2 KINASE;

EID: 84928387908     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.619502     Document Type: Article

References (44)

1. Miossec P., and Kolls, J.K. (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763-776
2. Volpe, E., Servant, N., Zollinger, R., Bogiatzi, S. I., Hupé, P., Barillot, E., and Soumelis, V. (2008) A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9, 650-657
3. Geremia, A., Arancibia-Cárcamo, C. V., Fleming, M. P., Rust, N., Singh, B., Mortensen, N. J., Travis, S. P., and Powrie, F. (2011) IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127-1133
4. Sandborn, W. J., Gasink, C., Gao, L. L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., Ghosh, S., de Villiers, W. J., Panaccione, R., Greenberg, G., Schreiber, S., Lichtiger, S., Feagan, B. G., and CERTIFI Study Group (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528
5. Strober, B. E., Crowley, J. J., Yamauchi, P. S., Olds, M., and Williams D. A. (2011) Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br. J. Dermatol. 165, 661-668
6. Longbrake, E. E., and Racke, M. K. (2009) Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev. Neurother. 9, 319-321
7. Vollmer, T. L., Wynn, D. R., Alam, M. S., and Valdes, J. (2011) A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult. Scler. 17, 181-191
8. Murray, P. J. (2007) The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178, 2623-2629
9. Vincenti, F., Tedesco Silva, H., Busque, S., O'Connell, P., Friedewald, J., Cibrik, D., Budde, K., Yoshida, A., Cohney, S., Weimar, W., Kim, Y. S., Lawendy, N., Lan, S. P., Kudlacz, E., Krishnaswami, S., and Chan, G. (2012) Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am. J. Transplant. 12, 2446-2456
10. Oyamada, A., Ikebe, H., Itsumi, M., Saiwai, H., Okada, S., Shimoda, K., Iwakura, Y., Nakayama, K. I., Iwamoto, Y., Yoshikai, Y., and Yamada, H. (2009) Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J. Immunol. 183, 7539-7546
11. Ortmann, R., Smeltz, R., Yap, G., Sher, A., and Shevach, E. M. (2001) A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J. Immunol. 166, 5712-5719
12. Liang, J., van Abbema, A., Balazs, M., Barrett, K., Berezhkovsky, L., Blair, W., Chang, C., Delarosa, D., DeVoss, J., Driscoll, J., Eigenbrot, C., Ghilardi, N., Gibbons, P., Halladay, J., Johnson, A., Kohli, P. B., Lai, Y., Liu, Y., Lyssikatos, J., Mantik, P., Menghrajani, K., Murray, J., Peng, I., Sambrone, A., Shia, S., Shin, Y., Smith, J., Sohn, S., Tsui, V., Ultsch, M., Wu, L. C., Xiao, Y., Yang, W., Young, J., Zhang, B., Zhu, B. Y., and Magnuson, S. (2013) Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J. Med. Chem. 56, 4521-4536
13. Norman, P. (2012) Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin. Ther. Pat. 22, 1233-1249
14. Zeqiraj E., and van Aalten, D.M. (2010) Pseudokinases-remnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol. 20, 772-781
15. Saharinen, P., Vihinen, M., and Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell. 14, 1448-1459
16. Saharinen, P., and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963
17. Posy, S. L., Hermsmeier, M. A., Vaccaro, W., Ott, K. H., Todderud, G., Lippy, J. S., Trainor, G. L., Loughney, D. A., Johnson, S. R. (2011) Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem. 54, 54-66
18. Kempson, J., Spergel, S. H., Guo, J., Quesnelle, C., Gill, P., Belanger, D., Dyckman, A. J., Li, T., Watterson, S. H., Langevine, C. M., Das, J., Moquin, R. V., Furch, J. A., Marinier, A., Dodier, M., Martel, A., Nirschl, D., Van Kirk, K., Burke, J. R., Pattoli, M. A., Gillooly, K., McIntyre, K. W., Chen, L., Yang, Z., Marathe, P. H., Wang-Iverson, D., Dodd, J. H., McKinnon, M., Barrish, J. C., and Pitts, W. J. (2009) Novel tricyclic inhibitors of IκB kinase. J. Med. Chem. 52, 1994-2005
19. Dyckman, A., Pitts, W. J., Belema, M., Gill, P., Kempson, J., Qiu, Y., Quesnelle, C., Spergel, S. H., and Zusi, F. C. (November 25, 2008) Imidazofused Oxazolo[4,5-B]pyridine and Imidazo-fused Thiazolo[4,5-B]pyridine Based Tricyclic Compounds and Pharmaceutical Compositions Comprising Same, United States Patent 7456194
20. Gillooly, K. M., Pattoli, M. A., Taylor, T. L., Chen, L., Cheng, L., Gregor, K. R., Whitney, G. S., Susulic, V., Watterson, S. H., Kempson, J., Pitts, W. J., Booth-Lute, H., Yang, G., Davies, P., Kukral, D. W., Strnad, J., McIntyre, K. W., Darienzo, C. J., Salter-Cid, L., Yang, Z., Wang-Iverson, D. B., and Burke, J. R. (2009) Periodic, partial inhibition of IκB kinase β-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 331, 349-360
21. Purandare, A. V., McDevitt, T. M., Wan, H., You, D., Penhallow, B., Han, X., Vuppugalla, R., Zhang, Y., Ruepp, S. U., Trainor, G. L., Lombardo, L., Pedicord, D., Gottardis, M. M., Ross-Macdonald, P., de Silva, H., Hosbach, J., Emanuel, S. L., Blat, Y., Fitzpatrick, E., Taylor, T. L., McIntyre, K. W., Michaud, E., Mulligan, C., Lee, F. Y., Woolfson, A., Lasho, T. L., Pardanani, A., Tefferi, A., Lorenzi, M. V. (2012) Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 26, 280-288
22. Otwinowski, Z., and Minor, W. Processing of x-ray diffraction data collected in oscillation mode (1987) Methods Enzymol. 276, 307-326
23. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674
24. Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., and Vagin, A. A. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367
25. Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, P., Sharff, A., Smart, O. S., Vonrhein, C., and Womack, T. O. (2011) BUSTER, Global Phasing Ltd., Cambridge, UK
26. Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010) Features and Development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
27. Davis, M. I., Hunt, J. P., Herrgard S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051
28. Beurel, E., and Jope, R. S. (2008) Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 283, 21934-21944
29. Nagashima, K., Sasseville, V. G., Wen, D., Bielecki, A., Yang, H., Simpson, C., Grant, E., Hepperle, M., Harriman, G., Jaffee, B., Ocain, T., Xu, Y., and Fraser, C. C. (2006) Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKK. Blood 107, 4266-4273
30. Freire, E. (2008) Do enthaply and entropy distinguish first in class from best in class? Drug Discov. Today 13, 869-874
31. Doyle M. L., Louie, G., Dal Monte P. R., and Sokoloski, T. D. (1995) Tight binding affinities determined from thermodynamic linkage to protons by titration calorimetry. Methods Enzymol. 259, 183-194
32. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258-5266
33. Gauzzi, M. C., Velazquez, L., McKendry, R., Mogensen, K. E., Fellous, M., and Pellegrini, S. (1996) Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271, 20494-20500
34. Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R., and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030
35. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O., Hubbard, S. R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759
36. Toms, A., Deshpande, A., McNally, R., Jeong, Y., Rogers, J. M., Kim, C. U., Gruner, S. M., Ficarro, S. B., Marto, J. A., Sattler, M., Griffin, J. D., and Eck, M. J. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20, 1221-1223
37. Couturier, N., Bucciarelli, F., Nurtdinov, R. N., Debouverie, M., Lebrun-Frenay, C., Defer, G., Moreau, T., Confavreux, C., Vukusic, S., Cournu-Rebeix, I., Goertsches, R. H., Zettl, U. K., Comabella, M., Montalban, X., Rieckmann, P., Weber, F., Müller-Myhsok, B., Edan, G., Fontaine, B., Mars, L. T., Saoudi, A., Oksenberg, J. R., Clanet, M., Liblau, R. S., and Brassat, D. (2011) Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 134, 693-703
38. Ban, M., Goris, A., Lorentzen, A. R., Baker, A., Mihalova, T., Ingram, G., Booth, D. R., Heard, R. N., Stewart, G. J., Bogaert, E., Dubois, B., Harbo, H. F., Celius, E. G., Spurkland, A., Strange, R., Hawkins, C., Robertson, N. P., Dudbridge, F., Wason, J., De Jager, P. L., Hafler, D., Rioux, J. D., Ivinson, A. J., McCauley, J. L., Pericak-Vance, M., Oksenberg, J. R., Hauser, S. L., Sexton, D., Haines, J., Sawcer, S., Wellcome Trust Case-Control Consortium (WTCCC), and Compston, A. (2009) Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur. J. Hum. Genet. 17, 1309-1313
39. Percy, M.J., and McMullin, M.F. (2005) The V617F JAK2 mutation and the myeloproliferative disorders. Hematol. Oncol. 23, 91-93
40. Constantinescu S.N., Leroy, E., Gryshkova, V., Pecquet, C., and Dusa, A. (2013) Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. Biochem. Soc. Trans. 41, 1048-1054
41. Giordanetto, F., and Kroemer, R.T. (2002) Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng. 15, 727-737
42. Pieri, L., Bogani, C., Guglielmelli, P., Zingariello, M., Rana, R. A., Bartalucci, N., Bosi, A., and Vannucchi, A. M. (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 94, 1537-1545
43. Staerk, J., Kallin, A., Demoulin, J. B., Vainchenker, W., and Constantinescu, S. N. (2005) JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 280, 41893-41899
44. Shide, K., Shimoda, K., Kamezaki, K., Kakumitsu, H., Kumano, T., Numata, A., Ishikawa, F., Takenaka, K., Yamamoto, K., Matsuda, T., and Harada, M. (2007) Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk. Res. 31, 1077-1084